-
公开(公告)号：US20140186352A1
公开(公告)日：2014-07-03
申请号：US14145583
申请日：2013-12-31
Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Inventor： Jiann-Shiun Lai , Hung-Ling Wang , Chao-Yang Huang , Ying-Yung Lok
IPC: C07K16/18
CPC classification number: C07K16/18 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
Abstract: An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.
Abstract translation: 能够结合到颗粒溶素的R64至R113的表位区并能够中和颗粒溶素活性的抗颗粒溶素抗体或其scFv或Fab片段。 抗体可以含有选自SEQ ID NO：82至SEQ ID NO：195的序列的序列，或者抗体可以含有选自SEQ ID NO：39至SEQ ID NO：76的序列的序列。 抗体可以是单克隆抗体。 用于治疗或预防不需要的免疫应答障碍的方法包括向有需要的受试者施用有效量的能够中和颗粒溶素活性的抗颗粒溶素抗体。 不想要的免疫应答障碍可以是SJS，TEN或GVHD。
-
公开(公告)号：US20020072078A1
公开(公告)日：2002-06-13
申请号：US09988837
申请日：2001-11-19
Inventor： Yi-Fen Tsai , Liahng-Yirn Liu , Hsueh-Fang Chen , Tai-Guang Wu , Jiuan Liu , Tong-Hsuan Chang
IPC: G01N033/567
CPC classification number: G01N33/56972 , G01N33/54326
Abstract: The present invention discloses a diagnostic kit for assaying a cell presenting specific surface specific antigen, comprising: a first complex, comprising a magnetic bead coated with a first ligand specific to the specific cell surface antigen; a second complex, comprising a second ligand specific to the common cell surface antigen and a signal generation means; and a magnetic support. The kit can be used for the quantitative and qualitative analysis of a cell sample containing specific cell surface antigen.
Abstract translation: 本发明公开了一种用于分析呈递特异性表面特异性抗原的细胞的诊断试剂盒，其包含：第一配合物，其包含涂覆有特定细胞表面抗原特异性的第一配体的磁珠; 第二配合物，其包含对所述共同细胞表面抗原特异性的第二配体和信号产生装置; 和磁性支架。 该试剂盒可用于含有特异性细胞表面抗原的细胞样品的定量和定性分析。
-
公开(公告)号：US20240218337A1
公开(公告)日：2024-07-04
申请号：US18396245
申请日：2023-12-26
Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Inventor： CHU-BIN LIAO , HUI-CHIEH YU , HSIEN-YU TSAI , WEN-BIN KE , MENG-TING CAI
CPC classification number: C12N9/12 , A61P35/00 , C07K16/2827 , G01N33/57484 , G01N33/6857 , A61K38/00 , C07K2317/52 , C07K2317/565 , C07K2319/33 , C12Y207/10001 , G01N2333/70503
Abstract: The present disclosure relates to a fusion protein comprising a Gas6 binding portion and an antigen binding portion comprising an anti-PD-L1 antibody or antigen-binding fragment thereof. The present disclosure also relates to a method for treating and/or detecting a cancer in a subject in need, and a kit for detecting a cancer in a sample.
-
公开(公告)号：US20240209095A1
公开(公告)日：2024-06-27
申请号：US18522809
申请日：2023-11-29
Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Inventor： SHU-PING YEH , CHENG-CHOU YU , YU-HSUN LO , JIN-YU WANG , MEI-CHI CHAN , CHAO-YANG HUANG , SZU-LIANG LAI
CPC classification number: C07K16/2827 , A61K45/06 , A61K47/6849 , A61P35/00 , A61K2039/505 , C07K2317/24 , C07K2317/565
Abstract: The present disclosure relates to an anti-PD-L1 antibody or an antigen-binding fragment thereof, comprising: a heavy chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs: 2 to 4, or 6 to 8; and a light chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs: 10 to 12, or 14 to 16. The present disclosure also relates to a pharmaceutical composition and a method for detecting expression of PD-L1 in a sample.
-
公开(公告)号：US11499139B2
公开(公告)日：2022-11-15
申请号：US16472108
申请日：2017-12-19
Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Inventor： Hsuan-Pu Chen , Hsin-Lin Lu , Chien-I Lin , Hsueh-Lin Lu , Tao-Tien Chen
Abstract: Described herein are specific CHO genomic sites for targeted insertion of exogenous genes. The sites are located within a sequence selected from SEQ ID NOs: 1-16.
-
Patent Agency Ranking
76.发明授权公开(公告)号：US10980853B2
公开(公告)日：2021-04-20
申请号：US16067376
申请日：2015-12-31
Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
Inventor： Dai-Hua Tsai , Tzung Hsien Lai , Tsui Hsu Chan , Yuh Shan Chung , Li-Chuan Hsu
IPC: A61K36/28 , A61K36/00 , A61K31/513 , A61K45/06 , A61K31/704 , A61P35/00 , A61K9/14
Abstract: The present invention provides a process for the preparation of a Crassocephalum crepidioides extract, and the extract prepared thereby. The present invention further relates to a pharmaceutical composition/combination comprising the Crassocephalum crepidioides extract. The use of the extract and the composition/combination comprising the extract in the prevention or treatment of cancer is also provided.
-
77.发明申请公开(公告)号：US20210009597A1
公开(公告)日：2021-01-14
申请号：US16958721
申请日：2018-12-26
Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Inventor： Shih-Chieh YEN , Chu-Bin LIAO , Hui-Chen WANG , Po-Ting CHEN , Yu-Chih PAN , Tsung-Hui LI , Bo-Rong CHEN , Shian-Yi CHIOU
IPC: C07D487/04 , A61P35/00
Abstract: Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.
-
公开(公告)号：US10745360B2
公开(公告)日：2020-08-18
申请号：US15326490
申请日：2015-06-15
Applicant: Development Center for Biotechnology , DCB-USA LLC
Inventor： Nan-Horng Lin , Chu-Bin Liao , Shao-Zheng Peng , Shih-Chieh Yen , Mann-Yan Kuo
IPC: C07D241/44 , C07D401/12 , A61P35/00 , C07D413/04 , C07D413/12 , A61P9/00 , A61P19/02 , A61P3/10 , A61P13/12
Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号：US20200087697A1
公开(公告)日：2020-03-19
申请号：US16470807
申请日：2017-12-29
Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Inventor： SHIH-CHONG TSAI , CHUN-CHUNG LEE , MENG-SHENG LEE , CHING-YAO CHEN , SHIH-HSIEN CHUANG , YI-JEN CHEN , WIN-YIN WEI
Abstract: A process for modifying glycoproteins is provided. The invention also provides a process for producing glycoprotein payload conjugates, as well as the conjugates produced thereby.
-
公开(公告)号：US20190308949A1
公开(公告)日：2019-10-10
申请号：US16340685
申请日：2017-10-09
Applicant: Development Center for Biotechnology
Inventor： Shao-Zheng Peng , Chu-Bin Liao , Hung-Kai Chen , Chen-Hsuan Ho , Hung-Jyun Huang , Shian-Yi Chiou
IPC: C07D401/12 , C07D401/14 , C07D241/52 , C07D413/04 , C07D413/14 , A61P35/00
Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.
-
-
-
-
-
-
-
-
-
Search Results
85
records
(took 0.02 seconds)
